GeneDx (NASDAQ:WGS) Price Target Increased to $19.00 by Analysts at BTIG Research

GeneDx (NASDAQ:WGS) had its price objective increased by BTIG Research from $15.00 to $19.00 in a report released on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

Separately, The Goldman Sachs Group lifted their price objective on GeneDx to $11.00 and gave the stock a neutral rating in a report on Monday, April 15th.

GeneDx Stock Up 55.2 %

WGS stock opened at $17.07 on Tuesday. GeneDx has a 1-year low of $1.16 and a 1-year high of $18.24. The business has a fifty day moving average price of $9.63 and a 200-day moving average price of $5.19. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.10 and a quick ratio of 2.95. The stock has a market capitalization of $444.67 million, a P/E ratio of -2.29 and a beta of 2.75.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.01. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. The firm had revenue of $57.42 million during the quarter, compared to analysts’ expectations of $57.00 million. Equities analysts forecast that GeneDx will post -2.02 earnings per share for the current fiscal year.

Insider Buying and Selling at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,253 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $10.59, for a total transaction of $34,449.27. Following the completion of the sale, the chief financial officer now owns 28,927 shares of the company’s stock, valued at $306,336.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other GeneDx news, CFO Kevin Feeley sold 3,253 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $10.59, for a total transaction of $34,449.27. Following the completion of the sale, the chief financial officer now owns 28,927 shares of the company’s stock, valued at $306,336.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Casdin Capital, Llc purchased 40,000 shares of the business’s stock in a transaction on Monday, March 4th. The shares were bought at an average cost of $8.74 per share, with a total value of $349,600.00. Following the acquisition, the director now directly owns 2,702,609 shares of the company’s stock, valued at approximately $23,620,802.66. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 21,249 shares of company stock valued at $228,370. Company insiders own 28.10% of the company’s stock.

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in WGS. Oracle Investment Management Inc. boosted its stake in shares of GeneDx by 14.9% in the third quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock worth $3,620,000 after acquiring an additional 128,731 shares during the period. Decheng Capital LLC bought a new position in shares of GeneDx in the fourth quarter worth about $285,000. Trellus Management Company LLC boosted its stake in shares of GeneDx by 55.0% in the third quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after acquiring an additional 54,976 shares during the period. Pathstone Family Office LLC boosted its stake in shares of GeneDx by 262.2% in the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after acquiring an additional 39,327 shares during the period. Finally, HighTower Advisors LLC boosted its stake in shares of GeneDx by 14.1% in the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock worth $865,000 after acquiring an additional 29,361 shares during the period. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.